PlainPill

Amantadine

The short answer. There isn't much data on Amantadine yet — 21 mentions, 5 with a clear outcome — so treat these numbers as anecdotal. It is well studied — 147 meta-analyses on PubMed.

What users report
40%helped5 reports · few reports
2 helped1 mixed2 didn't help

From 21 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
147
meta-analyses
243
RCTs
4,631
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Amantadine does, according to users

Of the people who reported each effect, the share who said it got better.

2 more with fewer than 3 reports
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 147 meta-analyses on PubMed ↗ · 243 randomized trials ↗

Lancet · 2024 · Meta-analysis / systematic review
Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis

Conclusion: Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir probably decreases the risk of symptomatic seasonal influenza in individuals at high risk for severe disease after exposure to seasonal influenza viruses. Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir might reduce the risk of symptomatic zoonotic influenza after exposure to novel influenza A viruses associated with severe disease in infected humans.

PubMed 39181596 ↗
JAMA Intern Med · 2025 · Meta-analysis / systematic review
Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis

Conclusion: This systematic review and meta-analysis found that baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza. All other antiviral drugs either probably have little or no effect, or uncertain effects on patient-important outcomes.

PubMed 39804622 ↗
J Head Trauma Rehabil · 2021 · Meta-analysis / systematic review
Pharmacological Treatment of Agitation and/or Aggression in Patients With Traumatic Brain Injury: A Systematic Review of Reviews

Conclusion: On the basis of the results of this literature review, the authors recommend avoiding benzodiazepines and haloperidol for treating agitation and/or aggression in the context of TBI. Atypical antipsychotics (olanzapine in particular) can be considered as practical alternatives for the as-needed management of agitation and/or aggression in lieu of benzodiazepines and haloperidol. Amantadine, β-blockers (propranolol and pindolol), antiepileptics, and methylphenidate can be considered for scheduled treatment of agitation and/or aggression in patients with TBI.

PubMed 33656478 ↗
Registered clinical trials

337 human trials on ClinicalTrials.gov test Amantadine — 198 completed, 22 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

The current US prescription label has no boxed warning.

Full label on DailyMed (NIH) ↗

FDA recalls

9 recalls of products named for Amantadine. Most recent:

  • 2026-03-04 · Class II: Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution. record ↗
  • 2023-06-07 · Class II: CGMP Deviations: Firm went out of business and could no longer continue stability studies. record ↗
  • 2021-06-02 · Class II: CGMP Deviations: Intermittent exposure to temperature excursion during storage. record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

20,181 adverse-event reports mention Amantadine. Most often reported:

  • Fall · 2,155
  • Hallucination · 1,556
  • Drug ineffective · 1,519
  • Fatigue · 1,405
  • Dyskinesia · 1,277
  • Gait disturbance · 1,186

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Amantadine E — an unlikely cause of liver injury. LiverTox entry ↗

US government research funding (NIH)

NIH has funded 19 research projects with Amantadine in the title, $10,149,745 in total (1985–2017). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Amantadine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

headache ×1depression ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I'm finding it effective personally at 150mg 2x a day. Although it feels like I'll need 200 to be effective by itself.”
HelpedRead the discussion ↗
“Amantadine has worked the best so far me but then after 2 year use, I feel like It didn't do much.”
MixedRead the discussion ↗
“Only one thing ive heard about here that actually gave me relief from adhd symptoms and its amantadine”
HelpedRead the discussion ↗
Top discussions (5)

Amantadine compared

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate